

Sunday 8 November 2026

13:00–13:45	Lunch, Exhibition and Scientific Posters	Hall 4
13:45–15:15	STEPS 12: The Giulio Maria Corbelli Workshop – A Community Initiative to Design the Pathway to a Durable ART-Free Control of HIV Infection <i>A workshop organised by the European AIDS Treatment Group (EATG)</i>	Clyde
Chair	Sean Hosein , <i>Science and Medicine Editor, Canadian AIDS Treatment Information Exchange (CATIE) and EATG, Toronto, Canada</i>	
13:45–13:50	Welcome note and introduction to the programme Sean Hosein	
13:50–14:00	An introduction to the EU2Control Platform Casper Rokx , <i>Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands</i>	
14:00–14:10	A summary of selected approaches in HIV cure research Mark Janse , <i>Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands</i>	
14:10–14:20	HIV trial platform and CAR-T Marius Trøseid , <i>Oslo University Hospital, Oslo, Norway</i>	
14:20–14:30	What can we learn from pregnancy and the fetus about HIV cure? Marion Pardons , <i>Charité Universitätsmedizin, Berlin, Germany</i>	
14:30–14:40	Why studying quality of life of people in HIV cure research is important Kevin Moody , <i>Academic Medical Centre, Amsterdam, The Netherlands</i>	
14:40–14:50	The IDUNN clinical trial Ole Schmeltz Søgaard , <i>Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark</i>	
14:50–15:00	Engaging with the community Tomer Einav , <i>BeCURE – Berlin Centre for HIV Cure Research, Charité, Berlin, Germany</i>	
15:00–15:15	Discussion All	
15:15–15:45	Coffee, Exhibition and Scientific Posters	Hall 4
15:45–17:00	Industry Symposium	Clyde
17:00–17:30	Coffee, Exhibition and Scientific Posters	Hall 4
17:30–17:50	Official Opening	Clyde
17:30–17:45	Welcome to the Congress Alexandra Calmy , <i>University of Geneva, Geneva, Switzerland</i> Chloe Orkin , <i>Queen Mary University of London, and Barts Health NHS Trust, London, UK</i>	
17:45–17:50	Welcome from Glasgow City Bailie Martha Wardrop , <i>representative from Lord Provost’s Office, Glasgow, UK</i>	

Sunday 8 November 2026

17:50–19:00	From Confusion to Clarity: Addressing Health Misinformation at Scale	Clyde
Co-chairs	Alexandra Calmy Chloe Orkin	
17:50–17:55	Welcome and introduction Chloe Orkin	
17:55–18:10	What do we do about scientific confusion vs vaccine mistrust? Boghuma Titanji, <i>Department of Medicine, Emory University, Atlanta, GA, USA</i>	
18:10–18:35	Misinformation and disinformation, definitions, how it manifests on social media, AI algorithms when it comes from a public health official source Kai Kupferschmidt, <i>Science Magazine, Berlin, Germany</i>	
18:35–19:00	Panel discussion, Q&A and close All	
19:00–19:45	Civic Reception <i>HIV Glasgow 2026 gratefully acknowledges the civic hospitality of the Lord Provost of Glasgow and Glasgow City Council</i>	Hall 4

Monday 9 November 2026

08:30–09:30	Industry Symposium	Clyde
09:30–10:00	Coffee, Exhibition and Scientific Posters	Hall 4
10:00–11:30	PrEP Today and Tomorrow: Challenges, Advances and Equitable Access	Clyde
Co-chairs	Justyna Kowalska, <i>Hospital for Infectious Diseases in Warsaw, Warsaw, Poland</i> Davide Moschese, <i>Università degli Studi di Milano, Milan, Italy</i>	
10:00–10:05	Welcome and introduction <i>Justyna Kowalska</i>	
10:05–10:20	Current PrEP and complex management <i>Jade Ghosn, Infectious Diseases and Sexual Health Clinic, Bichat University Hospital and Université Paris Cité School of Medicine, Paris, France</i>	
10:20–10:35	What's the future of PrEP, talking about once-monthly oral and longer duration injectables and the pipeline, including access <i>Lobna Gayeeb, Medicines Patent Pool – MPP, Geneva, Switzerland</i>	
10:35–10:50	PrEP use in key groups <i>Yevheniia Rudhenka, 100% Life, Ukraine</i>	
10:50–10:58	O21: Higher persistence on twice-yearly lenacapavir versus daily F/TDF for PrEP in the UK and France in the PURPOSE 5 study <i>Chloe Orkin, Queen Mary University of London, and Barts Health NHS Trust, London, UK</i>	
10:58–11:06	O22: Mind the gap: estimating the impact of HIV PrEP on the epidemic in Switzerland <i>Benjamin Hampel, Department of Public and Global Health University of Zurich, Zurich, Switzerland</i>	
11:06–11:30	Q&A and close All faculty including oral presenters	
11:30–12:15	Keynote Lecture: The Evolving Cure Landscape <i>Lock Lecture gifted by the Royal College of Physicians and Surgeons of Glasgow</i>	Clyde
Chair	Daniel Kuritzkes, <i>Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA</i>	
11:30–11:35	Welcome and introduction Daniel Kuritzkes	
11:35–12:05	What's happening in the cure space? <i>Ole Schmeltz Søgaard, Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark</i>	
12:05–12:15	Q&A and close	
12:15–13:45	Lunch, Exhibition and Scientific Posters	Hall 4
12:30–13:30	Industry Symposium	Clyde

Monday 9 November 2026

13:45–15:00	Clinical Case Studies <i>In collaboration with www.hiv-druginteractions.org</i>	Clyde
Facilitators	Saye Khoo , <i>Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK</i> Catia Marzolini , <i>University Hospital Lausanne, Lausanne, Switzerland, and University of Liverpool, Liverpool, UK</i> Fiona Marra , <i>University of Liverpool, Liverpool, UK</i>	
Discussants	Juan Ambrosioni , <i>HIV Unit, Infectious Disease Service, Hospital Clinic-IDIBAPS, Barcelona, Spain</i> Susanne Dam Nielsen , <i>Infectious Diseases, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark</i> Karine Lacombe , <i>Hôpital Saint Antoine, Paris, France</i>	
13:45–13:50	Welcome and introduction Saye Khoo	
13:50–14:10	Case 1: PrEP Facilitator: Catia Marzolini Case Presenters: Simon Collins , <i>HIV i-Base, London, UK</i> Benjamin Hampel , <i>Department of Public and Global Health, University of Zurich, Zurich, Switzerland</i>	
14:10–14:30	Case 2: INSTI vs boosted PI Facilitator: Saye Khoo Case Presenter: Marta Boffito , <i>Chelsea and Westminster Hospital NHS Foundation Trust, London, UK</i>	
14:30–14:50	Case 3: HIV coinfection with HEP B +/- HEP D Facilitator: Fiona Marra Case Presenter: Christoph Boesecke , <i>Bonn University Hospital, Bonn, Germany</i>	
14:50–15:00	Closing remarks Saye Khoo	
15:00–16:15	STIs and HPV in People with HIV: Current Perspectives and Emerging Solutions	Clyde
Co-chairs	Magdalena Ankiersztejn-Bartczak , <i>Foundation for Social Education, Warsaw, Poland</i> Bernard Surial , <i>Department of Infectious Diseases, Inselspital, University Hospital Bern, Switzerland</i>	
15:00–15:05	Welcome and introduction Bernard Surial	
15:05–15:15	To treat or not to treat (all diagnosed STIs)? – that is the question Michael Rayment , <i>Sexual Health and HIV, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK</i>	
15:15–15:25	New antibiotics for gonorrhoea Chris Kenyon , <i>Institute of Tropical Medicine Antwerp, Antwerp, Belgium, and University of Cape Town, Cape Town, South Africa</i>	
15:25–15:35	Rounding up the evidence around a single dose for HPV – is that OK for people with HIV? Deborah Konopnicki , <i>Infectious Diseases, Saint-Pierre University Hospital, Brussels, Belgium</i>	
15:35–15:45	Elimination of cervical cancer in Australia and Denmark and Global inequity Mark O'Reilly , <i>East Sydney Doctors and Taylor Square Private Clinic, Darlinghurst, NSW, Australia</i>	
15:45–16:15	Q&A and closing remarks All	

Monday 9 November 2026

16:15–16:40	Keynote Lecture: Hidden in Plain Sight: Why Advanced HIV Disease Demands Attention	Clyde
Chair	Iskandar Azwa , <i>Infectious Diseases Unit, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia</i>	
16:15–16:18	Welcome and introduction Iskandar Azwa	
16:18–16:40	Why Advanced HIV Disease Demands Attention Ajay Rangaraj , <i>Department of HIV, TB, Hepatitis and STIs, World Health Organization, Geneva, Switzerland</i>	
16:40–17:50	EACS Guidelines Session: 2026 Update <i>In collaboration with the European AIDS Clinical Society (EACS)</i>	Clyde
Co-chairs	Jasmini Alagaratnam , <i>HIV Medicine, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK</i> Juan Ambrosioni , <i>HIV Unit, Infectious Disease Service, Hospital Clinic-IDIBAPS, Barcelona, Spain</i> Jürgen Rockstroh , <i>HIV Outpatient Clinic, University of Bonn, Bonn, Germany</i>	
16:40–16:45	Welcome and introduction Juan Ambrosioni	
16:45–16:55	Antiretroviral treatment and prevention Annalisa Marinosci , <i>University Hospital of Geneva, Geneva, Switzerland</i>	
16:55–17:05	Co-infections Andrea Mastrangelo , <i>Centre Hospitalier Universitaire Vaudoise – CHUV, Lausanne, Switzerland</i>	
17:05–17:15	Paediatric HIV Paolo Paioni , <i>Division of Infectious Diseases and Hospital Epidemiology, University Children's Hospital Zurich, Zurich, Switzerland</i>	
17:15–17:30	Co-morbidities Abiu Sempere , <i>Hospital Clinic of Barcelona, Barcelona, Spain</i> Moisés Alberto Suárez-Zdunek , <i>Infectious Diseases, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark</i>	
17:30–17:50	Q&A, panel discussion and close Alasdair Bamford , <i>Great Ormond Street Hospital, London, UK</i> Alexandra Calmy , <i>University of Geneva, Geneva, Switzerland</i> Susanne Dam Nielsen , <i>Infectious Diseases, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark</i> Catia Marzolini , <i>University Hospital Lausanne, Lausanne, Switzerland, and University of Liverpool, Liverpool, UK</i> Cristiana Oprea , <i>Infectious Diseases, Victor Babes Hospital for Infectious and Tropical Diseases, Bucharest, Romania</i>	
17:50–18:15	Coffee, Exhibition and Scientific Posters	Hall 4
18:15–19:30	Industry Symposium	Clyde

Tuesday 10 November 2026

08:30–09:45	Industry Symposium	Clyde
09:45–10:15	Coffee, Exhibition and Scientific Posters	Hall 4
10:15–11:30	Novel Strategies and Treatment	Clyde
Chair	Claudia P Cortes , <i>Infectious Diseases, Universidad de Chile, Santiago, Chile</i> Chloe Orkin , <i>Queen Mary University of London, and Barts Health NHS Trust, London, UK</i>	
10:15–10:20	Welcome and introduction Chloe Orkin	
10:20–10:40	What do the new therapies offer? Roy Gulick , <i>Division of Infectious Diseases, Weill Cornell Medicine, New York City, NY, USA</i>	
10:40–10:55	New therapies, hard choices: Public health priorities and research gaps Alexandra Calmy , <i>University of Geneva, Geneva, Switzerland</i>	
10:55–11:07	O31: A 24-week phase 2a maintenance study of TMB-365/TMB-380 q8w in people with suppressed HIV-1 infection Martin Markowitz , <i>Irving Medical Center, Columbia University, Irvine, CA, USA</i>	
11:07–11:19	O33: Immunogenicity and associated safety of amtabafusp alfa, a bispecific T-cell engager, in a phase 1b study in people with HIV Princy Kumar , <i>MedStar Georgetown University Hospital, Washington, DC, USA</i>	
11:19–11:30	Close Claudia Cortes	
11:30–12:30	Prioritising Young Adults in Efforts to End HIV Transmissions and Improve Quality of Life for All <i>In collaboration with the British HIV Association (BHIVA)</i>	Clyde
Co-chairs	Caroline Sabin , <i>Institute for Global Health, University College London, London, UK</i> Tristan Barber , <i>Ian Charleson Day Centre, Royal Free London NHS Foundation Trust, London, UK</i>	
11:30–11:32	Welcome and introduction Caroline Sabin	
11:32–11:42	The UK's HIV Action Plan, BHIVA's contribution to this, and next steps for the other devolved nations. Why are young people a crucial group in the country's response to HIV? Tristan Barber	
11:42–11:57	How does the HIV Action Plan support young adults? Verity Sullivan , <i>Axess Sexual Health, University Hospitals of Liverpool Group, Liverpool, UK</i> Danny Whitebread , <i>London, UK</i>	
11:57–12:12	Addressing issues of specific relevance to young women with vertically acquired HIV, sharing experiences of ways in which clinics have evolved to support this group of women Mimie Chirwa , <i>Sexual Health and HIV, Bedfordshire NHS Foundation Trust, Luton, UK</i> Emma , <i>UK</i>	
12:12–12:27	Panel discussion All	
12:27–12:30	Close	

Tuesday 10 November 2026

12:30–14:00	Lunch, Exhibition and Scientific Posters	Hall 4
12:45–13:45	Industry Symposium	Clyde
14:00–14:35	Keynote Lecture: Vaccines for HIV and Emerging Viruses <i>Joep Lange and Jacqueline van Tongeren Keynote Lecture, dedicated to them in recognition of their commitment and passion to rid the world of HIV/AIDS</i>	Clyde
Chair	Linda-Gail Bekker, Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa	
14:00–14:05	Welcome and introduction Linda-Gail Bekker	
14:05–14:35	Vaccines for HIV and Emerging Viruses Robin Shattock, Infectious Diseases, Imperial College London, London, UK	
14:35–15:45	Regional Challenges and Solutions Around HIV Access and Implementation	Clyde
Co-chairs	Claudia P Cortes, Infectious Diseases, Universidad de Chile, Santiago, Chile Mitchell Warren, AVAC – Global Advocacy for HIV Prevention, New York City, NY, USA	
14:35–14:50	Welcome and setting the scene Mitchell Warren	
14:50–15:20	Regional discussants Africa: Cissy Kityo, Joint Clinical Research Centre, Kampala, Uganda Asia Pacific: Iskandar Azwa, Infectious Diseases Unit, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia Europe: Frederico Duarte, Infectious Diseases, Hospital Pedro Hispano - ULS de Matosinhos, Matosinhos, Portugal Andriy Klepikov, Alliance for Public Health, Kyiv, Ukraine, and President-Elect, International AIDS Society Latin America: Omar Sued, Pan American Health Organization, Washington, DC, WA, USA MENA: Roaa Alosaimi, HIV Centre of Excellence, East Jeddah Hospital, Jeddah, Saudia Arabia	
15:20–15:45	Panel discussion, Q&A and close All	
15:45–17:25	The Hepatitis Alphabet: What's the Latest?	Clyde
Co-chairs	Karine Lacombe, Hôpital Saint Antoine, Paris, France Gilles Wandeler, Bern University Hospital, Bern, Switzerland	
15:45–15:47	Welcome and introduction Karine Lacombe	
15:47–16:02	Let's not forget about hepatitis A Miłosz Parczewski, Department of Infectious Diseases, Pomeranian Medical University, Szczecin, Poland and Regional Centre for Digital Medicine, Szczecin, Poland	
16:02–16:17	Hepatitis B 2-drug regimen and re-activation Anna-Maria Geretti, Royal Free London NHS Trust, London, UK, and University of Rome Tor Vergata, Rome, Italy	
16:17–16:32	Novel treatments for viral hepatitis Lisa Sandmann, Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany	

Tuesday 10 November 2026

15:45–17:25	The Hepatitis Alphabet: What's the Latest? (continued)	Clyde
16:32–16:47	Artificial intelligence in cohort studies and clinical trials for chronic viral hepatitis <i>Anders Boyd, Inselspital, University of Bern, Bern, Switzerland</i>	
16:47–16:59	O34: Isolated hepatitis B core antibody and liver-related outcomes in people living with HIV enrolled in the Swiss HIV Cohort Study <i>Adrien Calame, Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals and Medical School, Geneva, Switzerland</i>	
16:59–17:11	O35: HBV outcomes after switching to long-acting cabotegravir plus rilpivirine in the Spanish RELATIVITY cohort <i>Luz Martín Carbonero, HIV Unit, Hospital Universitario La Paz, Madrid, Spain</i>	
17:11–17:23	O36: Hepatitis B after switch to long-acting cabotegravir/rilpivirine: data from the SCohoLART study <i>Angelo Roberto Raccagni, Infectious Diseases Unit; IRCCS San Raffaele Scientific Institute, Milan, Italy and Vita-Salute San Raffaele University, Milan, Italy</i>	
17:23–17:25	Close Gilles Wandeler	
17:25–17:45	Coffee, Exhibition and Scientific Posters	Hall 4 Forth Foyer
17:45–18:30	Oral Parallel Session 1: Cardiometabolic Complications	Clyde
Co-chairs	Peter Reiss, Global Health, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands Lene Ryom, Centre of Excellence for Health, Immunity and Infections – Rigshospitalet, University of Copenhagen, Copenhagen, Denmark	
17:45–17:50	Welcome and introduction Peter Reiss	
17:50–18:02	O37.1: Performance of the SMART2 cardiovascular risk model in people with HIV and prior atherosclerotic cardiovascular disease: a nationwide cohort study in the Netherlands <i>Rosa Elias, Department of Infectious Diseases, University Medical Centre Utrecht, Utrecht, Netherlands and Department of Internal Medicine, and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, Netherlands</i>	
18:02–18:14	O37.2: Statin use for primary prevention of cardiovascular disease among individuals with HIV in the Netherlands, impact of updated (inter)national guidelines <i>Colette Smit, Stichting HIV Monitoring, Amsterdam, Netherlands and Department of Infectious Diseases, Amsterdam University Medical Center, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands</i>	
18:14–18:26	O37.3: T-cell phenotypes and coronary artery disease in people with HIV <i>Moisés Alberto Suárez-Zdunek, Infectious Diseases, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark</i>	
18:26–18:30	Close Lene Ryom	

Tuesday 10 November 2026

17:45–18:30	Oral Parallel Session 2: Antiretroviral Treatment and Resistance	Lomond
Co-chairs	Brenda Crabtree-Ramírez , <i>Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico</i> Jonathan Schapiro , <i>National Hemophilia Center, Sheba Medical Center, Tel Aviv, Israel</i>	
17:45–17:50	Welcome and introduction Jonathan Schapiro	
17:50–18:02	O38.1: Treatment uptake and virological and immunological outcomes of cabotegravir+rilpivirine long-acting therapy versus dolutegravir or bictegravir-based regimens in people living with HIV: RESPOND HIV cohort collaboration Alisa Timiryasova , <i>Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark</i>	
18:02–18:14	O38.2: Long-term effectiveness of long-acting cabotegravir/rilpivirine in people with HIV harboring non-rilpivirine NNRTI resistance mutations: two-year results from the RELATIVITY cohort David Rial-Crestelo , <i>Hospital Universitario 12 de Octubre, imas12 Health Research Institute, Madrid, Spain and CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain</i>	
18:14–18:26	O38.3: Doravirine susceptibility in people living with HIV with multi-class antiretroviral resistance: a real-world cohort analysis Rocio Montejano , <i>Hospital Universitario La Paz, IdiPAZ, Madrid, Spain and CIBERINFEC, Madrid, Spain</i>	
18:26–18:30	Close Brenda Crabtree-Ramírez	
17:45–18:30	Oral Parallel Session 3: Under-served Populations	Forth
Co-chairs	Chloé Pasin , <i>SHARE Collaborative, Queen Mary University of London, London, UK</i> Romain Palich , <i>Immunology and Infectious Diseases, Paris Cité Université, Hôtel-Dieu Hospital, Paris, France</i>	
17:45–17:50	Welcome and introduction Chloé Pasin	
17:50–18:02	O39.1: Viral resistance and antiretroviral treatment regimens in French adults with perinatally acquired HIV-1 Thomas Guilhou , <i>Paris Cité University, AP-HP, Hôtel-Dieu Hospital, Immunology and Infectiology Department, Paris, France</i>	
18:02–18:14	O39.2: At the margins of the fringe: intersectional and structural inequities in HIV testing and healthcare linkage among migrants across 10 European countries – a community-led bio-behavioural cross-sectional study Haoyi Wang , <i>Department of Work and Social Psychology, Maastricht University, Maastricht, Netherlands and Viroscience Department, Rotterdam, Netherlands</i>	
18:14–18:26	O39.3: Addressing the data gap on recent migrants and HIV: understanding the experiences and long-acting treatment preferences of recent migrants living with HIV from the Ask Us Europe survey Megan Devonald , <i>Queen Mary University of London, London, UK</i>	
18:26–18:30	Close Romain Palich	

Wednesday 11 November 2026

08:30–09:45	Women Ageing with HIV: Beyond Viral Suppression Advancing Physical, Mental and Social Health <i>In collaboration with the European AIDS Treatment Group (EATG)</i>	Clyde
Co-chairs	Aisuluu Bolotbaeva, <i>EATG</i> Robert James, <i>EATG</i>	
08:30–08:35	Welcome and introduction Aisuluu Bolotbaeva and Robert James	
08:35–08:45	Community perspective Memory Sachikonye, <i>UK Community Advisory Board – UK-CAB and EATG, London, UK</i>	
08:45–09:00	Co-morbidities and cardiometabolic health Shema Tariq, <i>University College London, London, UK</i>	
09:00–09:12	Mental health and wellbeing of women ageing with HIV Berta Torres, <i>Infectious Diseases, Hospital Clinic, Barcelona, Spain</i>	
09:12–09:24	Healthy ageing amongst women with HIV Ellen Moseholm, <i>Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark</i>	
09:24–09:45	Panel discussion, Q&A and close All faculty, joined by Susan Cole-Haley, <i>Phoenix Health Movement, London, UK</i>	
09:45–10:15	Coffee, Posters and Exhibition	Hall 4
10:15–11:00	Weight Gain in People Living with HIV: A Roundtable Discussion <i>In collaboration with The Lancet HIV</i>	Clyde
Chair	Peter Hayward, <i>The Lancet HIV, London, UK</i>	
10:15–10:20	Welcome and introduction Peter Hayward	
10:20–11:00	Reflections on <i>The Lancet HIV</i> paper series due to be launched at the Congress Jennifer Manne-Goehler, <i>Mass General Brigham, Newton, MA, USA</i> Nomathemba Chandiwana, <i>Desmond Tutu Health Foundation, Cape Town, South Africa</i>	
11:00–11:02	There will be a two-minute silence for Armistice Day	SEC
11:02–12:00	When the Money Stops: Navigating Constraints and Protecting Critical Services	Clyde
Co-chairs	Angelina Namiba, <i>4M Mentor Mothers Network, London, UK</i> Alain Volny-Anne, <i>Bangkok, Thailand</i>	
11:02–11:05	Welcome and introduction Alain Volny-Anne	
11:05–11:20	HIV Treatment: Integrating HIV services in an era of global change Joseph Larmarange, <i>Institut de Recherche pour le Développement, CEPED, Paris, France</i>	
11:20–11:30	The effects funding cuts/challenges are having on the work of the community Magdalena Ankiersztejn-Bartczak, <i>Foundation for Social Education, Warsaw, Poland</i>	

Wednesday 11 November 2026

11:00–12:00	When the Money Stops: Navigating Constraints and Protecting Critical Services (continued)	Clyde
11:30–11:40	The effects funding cuts/challenges are having on the work of the community Solange Baptiste, <i>International Treatment Preparedness Coalition (ITPC) Global, Johannesburg, South Africa</i>	
11:40–12:00	Panel discussion, Q&A and close Facilitated by Omar Sued, <i>Pan American Health Organization, Washington, DC, USA</i>	
12:00–13:00	Hot Topics and Congress Close	Clyde
Co-chairs	Alexandra Calmy, <i>University of Geneva, Geneva, Switzerland</i> Chloe Orkin, <i>Queen Mary University of London, and Barts Health NHS Trust, London, UK</i>	
12:00–12:05	Welcome and introduction Alexandra Calmy	
12:05–12:17	O41: Bridging the financing cliff: adapting HIV service delivery across Southern, East, Central and West Africa Gordon Mwinkoma Tambro, <i>Society for AIDS in Africa, Accra, Ghana</i>	
12:17–12:29	O42: Dolutegravir resistance among people with repeated viraemia in a prospective routine HIV care cohort in Lesotho Niklaus D Labhardt, <i>Department of Clinical Research, University Hospital Basel, Basel, Switzerland</i>	
12:29–12:41	O43: Pharmacokinetics of long-acting injectable cabotegravir in pregnant and postpartum women in South Africa Catherine Orrell, <i>South Africa Medical Research Centre, Durban / Desmond Tutu Health Foundation, Cape Town, South Africa</i>	
12:41–12:53	O44: Real-world effectiveness of long-acting cabotegravir and rilpivirine in people with HIV-1 subtype A6: preliminary results from the multinational LACRIS study Milosz Parczewski, <i>Department of Infectious Diseases, Pomeranian Medical University, Szczecin, Poland and Regional Centre for Digital Medicine, Szczecin, Poland</i>	
12:53–13:00	Closing Remarks Alexandra Calmy Chloe Orkin	
13:00–14:00	Lunch	Forth and Gala Foyers

Oral Abstracts

Monday 9 November 2026

Full author lists for Oral Presentations from submitted abstracts

O21: Higher persistence on twice-yearly lenacapavir versus daily F/TDF for PrEP in the UK and France in the PURPOSE 5 study

Chloe Orkin¹, Jade Ghosn², Karine Lacombe³, Victoria Tittle⁴, Killian Quinn⁵, Amanda Clarke⁶, Gabriel Schembri⁷, Patrick Philibert⁸, Emily Clarke⁹, Hughes Cordel¹⁰, Stephen Taylor¹¹, Eric Cua¹², Iain Reeves¹³, Geoffroy Liegeon¹⁴, Jenna Yager¹⁵, Christoph Carter¹⁵, Yuliang Chen¹⁵, Pamela Wong¹⁵, Moupali Das¹⁵, Jean-Michel Molina¹⁴

¹SHARE Collaborative, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK. ²Université Paris Cité, AP-HP, Hôpital Bichat–Claude Bernard, Paris, France. ³Sorbonne Université, AP-HP, Hôpital Saint-Antoine, Paris, France. ⁴Chelsea and Westminster Hospital NHS Foundation Trust, London, UK. ⁵Caldecot Centre, King's College Hospital NHS Foundation Trust, London, UK. ⁶University Hospitals Sussex NHS Foundation Trust, Brighton, UK. ⁷Manchester Centre for Sexual Health, Manchester Royal Infirmary, Manchester, UK. ⁸Pôle Multidisciplinaire de Médecine Interne et Maladies Infectieuses, Hôpital Européen, Marseille, France. ⁹Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. ¹⁰Hôpital Avicenne, AP-HP, Bobigny, France. ¹¹University of Birmingham and Birmingham Heartlands Hospital, Birmingham, UK. ¹²University of Nice-Sophia Antipolis, Nice, France. ¹³Homerton Healthcare NHS Foundation Trust, London, UK. ¹⁴Université Paris Cité, AP-HP, Hôpital Saint-Louis and Lariboisière, INSERM U944, Paris, France. ¹⁵Gilead Sciences, Inc., Foster City, CA, USA

O22: Mind the gap: estimating the impact of HIV PrEP on the epidemic in Switzerland

Yuqian Wang¹, Katharina Kusejko², Bashkim Jaha², Roger Kouyos¹, Vanessa Christinet³, Florian Vock⁴, Dominique Braun⁵, Julia Notter⁶, Bernard Surial⁷, Matthias Cavassini⁸, Alexandra Calmy⁹, Luigia Elzi¹⁰, Patrick Schmid¹¹, Irene Abela², Andrea Farnham¹², Jan Fehr¹², Benjamin Hampel¹²

¹Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland. ²Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland. ³Medical Center du Flon, Lausanne, Switzerland. ⁴Swiss AIDS Federation, Zurich, Switzerland. ⁵Hirslanden Klinik Zurich, Zurich, Switzerland. ⁶Division of Infectious Diseases, University Hospital Basel, University of Basel, Basel, Switzerland. ⁷Inselspital Bern, University Hospital, University of Bern, Bern, Switzerland. ⁸Division of Infectious Diseases, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland. ⁹Division of Infectious Diseases, University Hospital Geneva, University of Geneva, Geneva, Switzerland. ¹⁰Division of Infectious Diseases, Regional Hospital Bellinzona, Bellinzona, Switzerland. ¹¹Division of Infectious Diseases, Infection Prevention and Travel Medicine, HOCH Health Ostschweiz, Cantonal Hospital St. Gallen (University Teaching and Research Hospital), St. Gallen, Switzerland. ¹²Department of Public & Global Health, Epidemiology, University of Zurich Biostatistics and Prevention Institute, Zurich, Switzerland

Tuesday 10 November 2026

Full author lists for Oral Presentations from submitted abstracts

O31: A 24-week phase 2a maintenance study of TMB-365/TMB-380 q8w in people with suppressed HIV-1 infection

Martin Markowitz¹, Jacob P. Lalezari², Edwin DeJesus³, Michael G. Sension⁴, Gordon Crofoot⁵, Moti Ramgopal⁶, Mezgebe Berhe⁷, Kuei-Ling Kuo⁸, Ying-An Lai⁸

¹Irving Medical Center, Columbia University, Irvine, CA, USA. ²Quest Clinical Research, San Francisco, CA, USA.

³Orlando Immunology Center, Orlando, FL, USA. ⁴CAN Community Health, Fort Lauderdale, FL, USA. ⁵Crofoot Research Center, Houston, TX, USA. ⁶Midway Immunology and Research Center, Fort Pierce, FL, USA. ⁷North Texas Infectious Diseases Consultants, Dallas, TX, USA. ⁸TaiMed Biologics Inc., Taipei City, Taiwan

O33: Immunogenicity and associated safety of amtabafusp alfa, a bispecific T-cell engager, in a phase 1b study in people with HIV

Kimberly Workowski¹, Yanan Zheng², Xiang Liu², Monika Sobczyk², Devi SenGupta², Elena Vendrame², Tina Chakrabarti², Princy Kumar³

¹Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. ²Gilead Sciences, Inc., Foster City, CA, USA. ³Division of Infectious Disease, MedStar Georgetown University Hospital, Washington, DC, USA

Oral Abstracts

Tuesday 10 November 2026 (continued)

Full author lists for Oral Presentations from submitted abstracts

034: Isolated hepatitis B core antibody and liver-related outcomes in people living with HIV enrolled in the Swiss HIV Cohort Study

Adrien Calame¹, Estelle Aymes², Lorin Bègré³, Gilles Wandeler³, Oksana Fiammingo¹, Matthias Cavassini⁴, Dominique Braun⁵, Alexandra Calmy¹, Maël Barthoulot², Olivier Ségéral¹, on behalf of the Swiss HIV Cohort Study

¹Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals and Medical School, Geneva, Switzerland. ²Clinical Research Centre, Geneva University Hospital, Geneva, Switzerland. ³Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. ⁴Division of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. ⁵Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

035: HBV outcomes after switching to long-acting cabotegravir plus rilpivirine in the Spanish RELATIVITY cohort

María del Mar Arcos Rueda¹, Miguel Torralba González de Suso², Juan Tiraboschi³, Analuz Fernandez³, Maria Jose Nuñez Orantos⁴, Jesus Troya García⁵, Luis Buzón⁶, María José Galindo Puerto⁷, Ruth Caballero Asensio⁸, María Remedios Alemán Valls⁹, María Belén Sánchez López¹⁰, Maria Jose Crusells Canales¹¹, Francisco Fanjul¹², Adrian Rodriguez¹³, Maria Carmen Fariñas Álvarez¹⁴, Laura Gisbert Pérez¹⁵, M.Carmen Navarro Sáez¹⁶, Ignacio de los Santos¹⁷, Carmen Hidalgo Tenorio¹⁸, Luis Enrique Morano Amado¹⁹, Enrique Bernal Morell²⁰, David Vinuesa García²¹, Maria Josefa De la Asunción Villaverde²², Alejandro David Bendala Estrada²³, Luz Martin Carbonero¹, on behalf of RELATIVITY Cohort Group

¹HIV Unit, Hospital Universitario La Paz, Madrid, Spain. ²Hospital Universitario Guadalajara, Guadalajara, Spain. ³Hospital Universitario de Bellvitge, Barcelona, Spain. ⁴Hospital Clínico San Carlos, Madrid, Spain. ⁵Hospital Universitario Infanta Leonor, Madrid, Spain. ⁶Hospital de Burgos, Burgos, Spain. ⁷Hospital Clínico Universitario de Valencia, Valencia, Spain. ⁸Hospital Universitario Miguel Servet, Zaragoza, Spain. ⁹Hospital Universitario de Canarias, Canarias, Spain. ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain. ¹¹Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. ¹²Hospital Universitario Son Espases, Mallorca, Spain. ¹³Hospital Universitario Son Llatzer (Palma de Mallorca), Mallorca, Spain. ¹⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain. ¹⁵Hospital Universitario Mutua de Terrassa, Barcelona, Spain. ¹⁶Parc Taulí Hospital Universitari, Sabadell, Spain. ¹⁷Hospital Universitario La Princesa, Madrid, Spain. ¹⁸Hospital Universitario Virgen de las Nieves, Granada, Spain. ¹⁹Hospital Universitario Álvaro Cunqueiro, Vigo, Spain. ²⁰Hospital General Universitario Reina Sofía, Murcia, Spain. ²¹Hospital Clínico San Cecilio, Granada, Spain. ²²Hospital de Denia Marina Salud, Alicante, Spain. ²³Hospital Universitario de Torrejón, Madrid, Spain

036: Hepatitis B after switch to long-acting cabotegravir/rilpivirine: data from the SCohoLART study

Angelo Roberto Raccagni^{1,2}, Tommaso Clemente¹, Riccardo Lolatto¹, Nicolò Capra¹, Serena Rolla¹, Hasson Hamid¹, Emanuela Messina¹, Vincenzo Spagnuolo^{1,2}, Elena Bruzzesi¹, Paola Striglia¹, Silvia Nozza^{1,2}, Antonella Castagna^{1,2}

¹Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy. ²Vita-Salute San Raffaele, Milan, Italy

037.1: Performance of the SMART2 cardiovascular risk model in people with HIV and prior atherosclerotic cardiovascular disease: a nationwide cohort study in the Netherlands

Rosa Elias^{1,2}, Tessa Reitsma³, Ferdinand Wit^{4,5}, Marc van der Valk^{4,5}, Casper Rokx², Annelies Verbon¹, Jannick Dorrestijn³, Berend van Welzen¹

¹Department of Infectious Diseases, University Medical Centre Utrecht, Utrecht, Netherlands. ²Department of Internal Medicine, and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, Netherlands. ³Department of Vascular Medicine and Endocrinology, University Medical Centre Utrecht, Utrecht, Netherlands. ⁴Stichting HIV Monitoring, Amsterdam, Netherlands. ⁵Department of Infectious Diseases, Amsterdam Infection and Immunity Institute, I&I, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands

Oral Abstracts

Tuesday 10 November 2026 (continued)

Full author lists for Oral Presentations from submitted abstracts

O37.2: Statin use for primary prevention of cardiovascular disease among individuals with HIV in the Netherlands, impact of updated (inter)national guidelines

Colette Smit^{1,2}, Ferdinand Wit^{1,2}, Dorine de Vries-Sluijs³, Jan den Hollander⁴, Kees Brinkman⁵, Berend van Welzen⁶, Anna Roukens⁷, Wouter Bierman⁸, Marc van der Valk^{1,2}, on behalf of the Athena Observational Cohort

¹Stichting HIV Monitoring, Amsterdam, Netherlands. ²Department of Infectious Diseases, Amsterdam University Medical Center, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands. ³Department of Medical Microbiology & Infectious Diseases, Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, Netherlands. ⁴Department of Internal Medicine and Infectious Diseases, Maasstad Ziekenhuis, Rotterdam, Netherlands. ⁵Department of Internal Medicine and Infectious Diseases, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands. ⁶Department of Infectious Diseases, University Medical Centre Utrecht, Utrecht, Netherlands.

⁷Department of Infectious Diseases, Leiden University Medical Centre, Leiden, Netherlands. ⁸Department of Internal Medicine/Infectious Diseases, University Medical Centre Groningen, Groningen, Netherlands

O37.3: T-cell phenotypes and coronary artery disease in people with HIV

Hans J. Hansen¹, Moises A. Suarez-Zdunek¹, Dina L. Møller¹, Ask Bock¹, Andreas D. Knudsen¹, Andreas Fuchs², Sisse R. Ostrowski^{3,4}, Thomas L. Benfield^{5,4}, Klaus F. Kofoed^{2,4}, Susanne D. Nielsen^{1,4}

¹Department of Infectious Diseases, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark.

²Department of Cardiology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark. ³Department of Clinical Immunology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark. ⁴Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

⁵Department of Infectious Diseases, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark

O38.1: Treatment uptake and virological and immunological outcomes of cabotegravir+rilpivirine long-acting therapy versus dolutegravir or bictegravir-based regimens in people living with HIV: RESPOND HIV cohort collaboration

Alisa Timiryasova¹, Lauren Greenberg¹, Katharina Kusejko^{2,3}, Lene Ryom^{1,4}, on behalf of the RESPOND Study Group

¹Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. ²Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. ³Institute of Medical Virology, University of Zurich, Zurich, Switzerland. ⁴Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Oral Abstracts

Tuesday 10 November 2026 (continued)

Full author lists for Oral Presentations from submitted abstracts

038.2: Long-term effectiveness of long-acting cabotegravir/rilpivirine in people with HIV harboring non-rilpivirine NNRTI resistance mutations: two-year results from the RELATIVITY cohort

David Rial-Crestelo^{1,2}, Jara Llenas-García^{3,2}, Carmen Hidalgo-Tenorio⁴, Jesús Troya García⁵, Noemí Cabello-Clotet⁶, María José Galindo Puerto⁷, María Remedios Alemán⁸, Miguel Torralba González de Suso⁹, Luis Buzón¹⁰, Adrián Rodríguez¹¹, Sonia Calzado Isbert¹², María Aguilera García¹³, Luis Enrique Morano Amado¹⁴, David Vinuesa García¹⁵, Enrique Bernal Morell¹⁶, Rosa María Martínez Álvarez¹⁷, Analuz Fernández¹⁸, María del Carmen Montero Hernández¹⁹, Cristina Díez Romero²⁰, Ruth Calderón Hernáiz²¹, Desirée Pérez Martínez²², Laura Gisbert Pérez²³, Víctor Arenas García²⁴, Cristina Escrich²⁵, María Carmen Fariñas Álvarez²⁶, Ana Lucas Dato²⁷, Juan Emilio Losa García²⁸, Hadrián Pernas Pardavila²⁹, Juan Carlos Gainzarain³⁰, Miriam Estebáñez³¹, Patricia Barragán Gallo³², Marta Clavero Olmos³³, Miguel Vicente Egidio Murciano³⁴, Óscar Luis Ferrero Benítez³⁵, Luz Martín-Carbonero^{3,2}, on behalf of the RELATIVITY Cohort Group

¹Hospital Universitario 12 de Octubre, imas12 Health Research Institute, Madrid, Spain. ²CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain. ³Hospital Universitario La Paz, IdiPAZ Health Research Institute, Madrid, Spain. ⁴Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria de Granada (IBS-Granada), Granada, Spain. ⁵Hospital Universitario Infanta Leonor, Madrid, Spain. ⁶Hospital Clínico San Carlos, Madrid, Spain. Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain. ⁷Hospital Clínico Universitario de Valencia, Valencia, Spain. ⁸Hospital Universitario de Canarias, Tenerife, Spain. ⁹Hospital Universitario de Guadalajara, Guadalajara, Spain. ¹⁰Hospital de Burgos, Burgos, Spain. ¹¹Hospital Universitario Son Llàtzer, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain. ¹²Parc Taulí Hospital Universitari, Sabadell, Spain. Institut d'Investigació i Innovació Parc Taulí (I3PT), Sabadell, Spain. ¹³Hospital Universitario de La Princesa, Madrid, Spain. ¹⁴Álvaro Cunqueiro University Hospital, Vigo, Spain. ¹⁵Hospital Clínico San Cecilio-PTS, Granada, Spain. ¹⁶Hospital General Universitario Reina Sofía, Murcia, Spain. ¹⁷Hospital Universitario Miguel Servet, Zaragoza, Spain. ¹⁸Bellvitge University Hospital, Barcelona, Spain. Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. ¹⁹Hospital Universitario de Torrejón, Madrid, Spain. ²⁰Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain. ²¹Hospital Universitario de Fuenlabrada, Madrid, Spain. ²²Hospital Universitario San Agustín, Avilés, Spain. ²³Hospital Universitario Mutua Terrassa, Barcelona, Spain. ²⁴Hospital Universitario de Cabueñes, Gijón, Spain. ²⁵Hospital Verge de la Cinta, Tortosa, Spain. ²⁶Hospital Universitario Marqués de Valdecilla, Santander, Spain. ²⁷Hospital Comarcal de la Vega Baja, Alicante, Spain. ²⁸Hospital Universitario Fundación Alcorcón, Madrid, Spain. ²⁹Complejo Hospitalario Universitario de Pontevedra, Instituto de Investigación Sanitaria Galicia Sur, Pontevedra, Spain. ³⁰Hospital Universitario de Álava, Vitoria-Gasteiz, Spain. ³¹Hospital Central de la Defensa Gómez Ulla, Madrid, Spain. ³²Hospital Residencia Sant Camil, Barcelona, Spain. ³³Hospital Universitario Infanta Elena, Madrid, Spain. ³⁴Hospital Universitario San Jorge, Huesca, Spain. ³⁵Hospital Universitario de Basurto, Bilbao, Spain

038.3: Doravirine susceptibility in people living with HIV with multi-class antiretroviral resistance: a real-world cohort analysis

Alejandro De Gea-Grela¹, Jose I. Bernardino¹, Luz Martin-Carbonero¹, Jara Llenas-Garcia¹, Carmen Busca¹, María Del Mar Arcos-Rueda¹, Rosa De Miguel-Buckley¹, Maria Luisa Montes¹, Rafael Mican¹, Juan Gonzalez-Garcia¹, Jose R. Arribas¹, Rocio Montejano^{1,2}

¹Hospital Universitario La Paz . IdiPAZ, Madrid, Spain. ²CIBERINFEC, Madrid, Spain

Oral Abstracts

Tuesday 10 November 2026 (continued)

Full author lists for Oral Presentations from submitted abstracts

039.1: Viral resistance and antiretroviral treatment regimens in French adults with perinatally acquired HIV-1

Thomas Guilhou¹, Valentine Fihman², Patricia Brazille³, Dominique Batisse¹, Narjis Boukli⁴, Clementine De la Porte¹, Claudine Duvivier⁵, Marina Karmochkine¹, Odile Launay⁶, Alice-Andrée Mariaggi², Juliette Pavie¹, Anne Rachline¹, Laurence Slama¹, Jean-Paul Viard¹, Pierre Frange², Romain Palich¹

¹Paris Cité University, AP-HP, Hôtel-Dieu Hospital, Immunology and Infectiology Department, Paris, France. ²Paris Cité University, AP-HP, Cochin Hospital, Department of Virology, Paris, France. ³Paris Cité University, AP-HP, Hôtel-Dieu Hospital, Espace Santé Jeunes, Paris, France. ⁴Paris Cité University, AP-HP, Georges-Pompidou European Hospital, Department of Virology, Paris, France. ⁵University of Paris Cité, AP-HP, Necker Pasteur Infectiology Centre, Department of Infectious Diseases, Paris, France. ⁶Université Paris Cité Inserm, AP-HP, Hôpital Cochin, CIC Cochin Pasteur, Paris, France

039.2: At the margins of the fringe: intersectional and structural Inequities in HIV testing and healthcare linkage among migrants across 10 European countries – a community-led bio-behavioural cross-sectional study

Haoyi Wang^{1,2}, Hala Majdoub³, Anne Flaherty-Gupta³, Kim Isip⁴, Pedro Barrios Sanchez⁵, Francesco Bellissimo⁶, Yiannis Charilaou⁷, Christos Krasidis⁷, Rosaline M'Bayo⁸, Stephen Amoah⁸, Trésors Kouadio⁹, Robert Ian Kibet Ouko Babu¹⁰, Ann Piercy¹¹, Abimbola Ajomale¹², Moro Yapha¹³, Etinosa Erevbenagie-Johnbull¹⁴, Letonde Hermine Gbedo¹⁵, Kai Jonas¹, Hanne Zimmermann¹, Denis Onyango³

¹Department of Work and Social Psychology, Maastricht University, Maastricht, Netherlands. ²Viroscience Department, Rotterdam, Netherlands. ³Africa Advocacy Foundation, London, UK. ⁴Association PASTT, Paris, France. ⁵Asociacion Karibu, Madrid, Spain. ⁶LHIVE Diritti e Prevenzione, Catania, Italy. ⁷AIDS Solidarity Movement, Nicosia, Cyprus. ⁸Afrikaherz (VIA e.V.), Berlin, Germany. ⁹Plateforme Prévention SIDA, Brussels, Belgium. ¹⁰Open Paths Athens, Athens, Greece. ¹¹HIV Ireland, Dublin, Ireland. ¹²Noaks Ark Mosaik, Malmö, Sweden. ¹³Fixpunkt e.V., Berlin, Germany. ¹⁴Generation for Change CY, Nicosia, Cyprus. ¹⁵Comitato per i Diritti Civili delle Prostitute, Trieste, Italy

039.3: Addressing the data gap on recent migrants and HIV: understanding the experiences and long-acting treatment preferences of recent migrants living with HIV from the Ask Us Europe survey

Megan Devonald¹, Chloé Pasin¹, Melanie Smuk¹, Rebecca Mbewe¹, Angelina Namiba², Marcel Dams³, Matthew Hodson⁴, Nicoletta Policek⁵, Alain Volny-Anne^{6,7}, Luís Mendão^{8,9}, Magdalena Ankiersztejn-Bartczak¹⁰, Juddy Otti¹¹, Casper Rokx¹², Frederico Duarte¹³, Sophie Strachan^{11,1}, Marc van der Valk¹⁴, David Jilich^{15,16}, Bogusz Aksak-Wąs¹⁷, Christophe Rouquette¹⁸, Sarah Brunel¹⁸, Thierry Tran¹⁸, Ann Piercy¹⁹, Simona Saluzzo²⁰, Chloe Orkin¹, on behalf of Ask Us Steering Group

¹Queen Mary University of London, London, UK. ²4M Mentor Mothers, London, UK. ³Independent Sexual Counselor and Sexual Educator, Berlin, Germany. ⁴Independent, London, UK. ⁵European Community Led Observatory on Ageing and HIV, Edinburgh, UK. ⁶Ask Us Steering Group, Paris, France. ⁷EATG, Paris, France. ⁸Ask Us Steering Group, Lisbon, Portugal. ⁹GAT Portugal, Lisbon, Portugal. ¹⁰Foundation for Social Education, Warsaw, Poland. ¹¹Sophia Forum, London, UK. ¹²Erasmus University Medical Center, Rotterdam, Netherlands. ¹³Hospital Pedro Hispano, Matosinhos, Portugal. ¹⁴Amsterdam UMC, Amsterdam, Netherlands. ¹⁵Charles University, Prague, Czechia. ¹⁶University Hospital Bulovka, Prague, Czechia. ¹⁷Pomeranian Medical University, Szczecin, Poland. ¹⁸TRT-5 CHV, Paris, France. ¹⁹HIV Ireland, Dublin, Ireland. ²⁰Medical University of Vienna, Vienna, Austria

Wednesday 11 November 2026

Full author lists for Oral Presentations from submitted abstracts

041: Bridging the financing cliff: adapting HIV service delivery across Southern, East, Central and West Africa

Gordon Mwinkoma Tambro, Luc Armand H. Bodea

Society for AIDS in Africa, Accra, Ghana

Oral Abstracts

Wednesday 11 November 2026 (continued)

Full author lists for Oral Presentations from submitted abstracts

O42: Dolutegravir resistance among people with repeated viraemia in a prospective routine HIV care cohort in Lesotho

Anna Klicpera¹, Maren Röhl¹, Blaise Lukau², Giuliana Sanchez Samaniego¹, Moleboheng Mokebe², Lipontso Motaboli², Irene Ayakaka², Roger D. Kouyos^{3,4}, Gioia Wick^{3,4}, Tom Loosli^{3,4}, Richard Lessels^{5,6}, Shirelle Janine Naidoo⁶, Jennifer Giandhari⁶, Nadine Tschumi¹, Jennifer Anne Brown^{1,3}, Niklaus D. Labhardt¹

¹Department of Clinical Research, University Hospital Basel, Basel, Switzerland. ²SolidarMed Lesotho, Maseru, Lesotho. ³Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland. ⁴Institute of Medical Virology, University of Zurich, Zurich, Switzerland. ⁵Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. ⁶KwaZulu-Natal Research Innovation and Sequencing Platform, University of KwaZulu-Natal, Durban, South Africa

O43: Pharmacokinetics of long-acting injectable cabotegravir in pregnant and postpartum women in South Africa

Dvora Joseph Davey^{1,2}, Lauren Jennings³, Rufaro Mvdudu³, Chantel Schreuder³, Elton Mukonda⁴, Nyiko Mashele³, Lubbe Wiesner⁴, Landon Myer⁴, Saye Khoo⁵, Catriona Waitt⁵, Linda-Gail Bekker³, Catherine Orrell^{6,3}

¹Infectious Disease Medicine, Los Angeles, CA, USA. ²Epidemiology and Biostatistics, Cape Town, South Africa. ³Desmond Tutu Health Foundation, Cape Town, South Africa. ⁴University of Cape Town, Cape Town, South Africa. ⁵University of Liverpool, Liverpool, UK. ⁶South Africa Medical Research Centre, Durban, South Africa

O44: Real-world effectiveness of long-acting cabotegravir and rilpivirine in people with HIV-1 subtype A6: preliminary results from the multinational LACRIS study

Miłosz Parczewski^{1,2}, Aleksandra Szymczak³, Iwona Cielniak^{4,5}, Ewa Siwak^{4,6}, Amelie Berner⁷, David Jilich⁸, Zuzana A. Lakatošová⁸, Wiktor Łukasik³, Maria Hlebowicz⁹, Anita Olczak¹⁰, Bartosz Szetela^{3,11}, Bogusz Aksak-Was¹, Elżbieta Mularska¹², Paweł Jakubowski¹³, Karolina Sorbian-Gajewska¹⁴, Anders Boyd^{15,16}, Pavel Khaykin⁷

¹Chair and Department of Infectious Diseases, Pomeranian Medical University, Szczecin, Poland. ²Regional Centre for Digital Medicine, Szczecin, Poland. ³All Saint's Clinic, Wrocławskie Centrum Zdrowia SP ZOZ, Wrocław, Poland. ⁴Hospital for Infectious Diseases, Warsaw, Poland. ⁵Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University, Warsaw, Poland. ⁶Department of Infectious and Tropical Diseases and Hepatology, Warsaw Medical University, Warsaw, Poland. ⁷MainFachArzt, Frankfurt on Main, Germany. ⁸Department of Infectious Diseases, 1st, 2nd and 3rd Medical Faculty, Charles University and Faculty Hospital Bulovka, Prague, Czechia. ⁹Department of Family Medicine and Infectious Diseases, University of Warmia and Mazury, Olsztyn, Poland. ¹⁰Department of Infectious Diseases and Hepatology, Faculty of Medicine, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. ¹¹Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies, Wrocław Medical University, Wrocław, Poland. ¹²Department of Infectious Diseases, Regional Hospital Chorzów, Chorzów, Poland. ¹³Szpital Pomorskie, Gdańsk, Poland. ¹⁴Clinical Trials Support Center, Pomeranian Medical University, Szczecin, Poland. ¹⁵Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. ¹⁶Department of Infectious Diseases, Amsterdam Institute for Infection & Immunity (AII) Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands